Coin Press - Israel riled by US-Iran pact

NYSE - LSE
CMSC 0.22% 22.79 $
NGG -1.93% 79.99 $
GSK -2.38% 49.365 $
BP 2.98% 43.155 $
AZN -2.64% 180.888 $
RIO 1.73% 108.263 $
RELX 4.96% 34.5 $
VOD -0.07% 14.95 $
BCE -0.3% 25.035 $
JRI -0.94% 12.8 $
BTI -0.42% 61.53 $
RBGPF -2.44% 61.5 $
RYCEF -6.64% 16.88 $
BCC -2.61% 67.73 $
CMSD -0.31% 22.858 $

Israel riled by US-Iran pact




The United States and Israel entered the spring of 2026 locked in an unprecedented conflict with Iran. On 28 February the two allies launched a joint offensive aimed at destroying Iran’s ballistic‑missile programme, curbing its support for militant proxies and forcing an end to its nuclear ambitions. The campaign quickly spread across the region: Iranian forces responded with ballistic‑missile salvos and drone attacks, and the United States imposed a naval blockade on Iranian ports. Iran retaliated by closing the Strait of Hormuz, a narrow waterway through which a fifth of the world’s oil flows. By early April both sides had agreed to a fragile ceasefire, but the war’s economic and human cost, coupled with mounting pressure from Gulf Arab states to restore trade, propelled Washington to seek a negotiated settlement.

President Donald Trump has now circulated a draft agreement that would reopen the Strait of Hormuz to commercial shipping, lift the U.S. blockade and unlock up to $12 billion of Iran’s frozen assets. Under the memorandum of understanding, shipping lanes would return to pre‑war levels within a month, and a 60‑day negotiating period would be devoted to the future of Iran’s nuclear programme. Discussions on highly enriched uranium, centrifuges and International Atomic Energy Agency supervision would begin only after trade resumed. Iran would renounce nuclear weapons, but its stockpiles and missile arsenal would not be dismantled at this stage. The deal also calls for a permanent ceasefire that would extend to Lebanon, where Israeli forces have been engaged in a separate conflict with Hezbollah. As a diplomatic sweetener, Washington has urged Saudi Arabia, Qatar, Pakistan and other regional powers to normalise relations with Israel by joining the Abraham Accords.

In Israel the proposal has provoked a storm of indignation. Senior officials, speaking on condition of anonymity, have branded the emerging accord a “bad deal”. Their chief complaint is that the draft postpones serious constraints on Iran’s nuclear and missile programmes, creating the risk that Tehran will pocket sanctions relief, rebuild its economy and rearm its proxies while negotiations drag on. Israeli strategists note that the memorandum says nothing about Iran’s long‑range missiles or its network of regional militias. They fear that a temporary ceasefire would allow Iran’s allies in Lebanon, Syria and Yemen to regroup and that the release of billions of dollars would enable Tehran to reconstitute military facilities damaged during the war.

Opposition leader Yair Lapid, who is attempting to unseat Prime Minister Benjamin Netanyahu later this year, has condemned the plan as “bad for Israel, bad for the region [and] bad for the citizens of Iran”. Lapid has criticised Mr Netanyahu for failing to influence Washington’s negotiating position and warns that Israel’s ability to shape American policy is at an all‑time low. Other Israeli commentators describe the draft as a strategic failure: the war began with publicly declared goals of toppling Iran’s theocratic government, ending its ballistic‑missile threat and severing its ties to militant groups, yet the proposed agreement delivers none of those outcomes. Analysts at the Institute for National Security Studies argue that the enormous gap between the war’s ambitions and the terms of the emerging deal shows how little the campaign’s architects understood Iran. Some call it a capitulation that leaves Iran in a stronger position than before the war.

Security officials are particularly alarmed by the prospect of constraints on Israeli military operations in Lebanon and Gaza. The draft calls for a permanent ceasefire not just in the Persian Gulf but across the region, including southern Lebanon where Israeli troops have seized strategic positions and where daily exchanges of fire with Hezbollah have continued despite the pause in the broader war. Israeli commanders insist on “freedom of action” to strike Iranian targets and proxies; they fear that a formal ceasefire would tie their hands and allow Hezbollah to entrench itself further along the northern border. The idea of including Hezbollah in the ceasefire, reportedly floated by Tehran, is anathema to the Israel Defense Forces.

The financial dimension of the proposed deal is another source of anger. Iran’s government is demanding access to billions of dollars held abroad to stabilise its economy after months of conflict. For Israel, the thought of unlocking those funds conjures memories of the 2015 nuclear agreement, which lifted sanctions and allowed Iran to re‑enter oil markets. Hawks in both Israel and the United States warn that injecting cash into Iran’s coffers will embolden the Revolutionary Guard Corps and enable renewed investment in missile development and proxy warfare. These critics argue that pressure—not relief—is the only way to force Tehran to dismantle its nuclear infrastructure and curb its regional ambitions. Some even say they would prefer a return to open conflict to the signing of a weak agreement that leaves Iran intact.

Israelis are also wary of the diplomatic gambit tied to the deal. President Trump has declared that it should be “mandatory” for countries such as Saudi Arabia, Qatar and Pakistan to recognise Israel as part of the agreement. Pro‑Israel voices in the United States have welcomed the idea, but regional experts point out that Gulf states are not prepared to normalise relations at a time when Israel is still waging wars in Lebanon and Gaza and when Palestinian casualties have fuelled widespread anger. Saudi Arabia has repeatedly said it will not normalise relations without a Palestinian state based on the 1967 borders. For Israel, therefore, the promise of new diplomatic ties offers little comfort; what matters is security, and the current draft does not guarantee it.

Beyond Israel, the emerging agreement has drawn criticism from Republican hawks in Washington. Senators Lindsey Graham, Ted Cruz and Roger Wicker have all warned that a 60‑day ceasefire that reopens the Strait of Hormuz while leaving Iran’s nuclear and missile capabilities untouched would be a “disaster”, a “nightmare” and a “disastrous mistake”. Former secretary of state Mike Pompeo has derided the proposal as a retreat from the “America First” stance, arguing that Tehran should not receive a penny until its capability to threaten U.S. allies is eliminated. These voices echo the concerns of Israeli officials who fear that the balance of power in the region will shift in Iran’s favour if the United States compromises.

The uproar in Jerusalem is compounded by a feeling of marginalisation. Reports in the Israeli press suggest that Mr Netanyahu has been largely sidelined in negotiations, with Washington seeking input from Gulf allies and Pakistan instead. A senior Israeli security official recently lamented that “Israeli interests were not taken into account throughout the negotiations”, noting that Israel might now face restrictions on its ability to act in Lebanon and Gaza despite fighting alongside the United States in Iran. Such perceived neglect has fuelled domestic criticism of Mr Netanyahu and heightened the sense of betrayal that underpins Israel’s fury at the emerging deal.

As negotiations continue, the gap between Israeli expectations and the draft agreement’s provisions remains wide. Israel entered the conflict hoping to eliminate a strategic rival and reshape the Middle East. It now confronts the prospect of a ceasefire that freezes the status quo, leaves Iran’s regime intact, and imposes constraints on Israel’s military freedom. Unless Washington and Tehran can produce a final agreement that addresses Israel’s security concerns—particularly the dismantling of Iran’s missile and nuclear capabilities and the curtailment of its proxies—the anger emanating from Jerusalem is unlikely to subside. The fate of the war, the security of the Gulf and the future of regional diplomacy all hinge on whether these divergent interests can be reconciled in the weeks ahead.



Featured


Long live Ukraine - Хай живе Україна - Да здравствует Украина

Es lebe die Ukraine - Да здравствует Украина - Long live Ukraine - Хай живе Україна - Nech žije Ukrajina - Länge leve Ukraina - תחי אוקראינה - Lang leve Oekraïne - Да живее Украйна - Elagu Ukraina - Kauan eläköön Ukraina - Vive l'Ukraine - Ζήτω η Ουκρανία - 乌克兰万岁 - Viva Ucrania - Ať žije Ukrajina - Çok yaşa Ukrayna - Viva a Ucrânia - Trăiască Ucraina - ウクライナ万歳 - Tegyvuoja Ukraina - Lai dzīvo Ukraina - Viva l'Ucraina - Hidup Ukraina - تحيا أوكرانيا - Vivat Ucraina - ขอให้ยูเครนจงเจริญ - Ucraina muôn năm - ژوندی دی وی اوکراین - Yashasin Ukraina - Озак яшә Украина - Živjela Ukrajina - 우크라이나 만세 - Mabuhay ang Ukraine - Lenge leve Ukraina - Nyob ntev Ukraine - Да живее Украина - გაუმარჯოს უკრაინას - Hidup Ukraine - Vivu Ukrainio - Længe leve Ukraine - Živjela Ukrajina - Жыве Украіна - Yaşasın Ukrayna - Lengi lifi Úkraína - Lank lewe die Oekraïne

Stargate project, Trump and the AI war...

In a dramatic return to the global political stage, former President Donald J. Trump, as the current 47th President of the United States of America, has unveiled his latest initiative, the so-called ‘Stargate Project,’ in a bid to cement the United States’ dominance in artificial intelligence and outpace China’s meteoric rise in the field. The newly announced programme, cloaked in patriotic rhetoric and ambitious targets, is already stirring intense debate over the future of technological competition between the world’s two largest economies.According to preliminary statements from Trump’s team, the Stargate Project will consolidate the efforts of leading American tech conglomerates, defence contractors, and research universities under a centralised framework. The former president, who has long championed American exceptionalism, claims this approach will provide the United States with a decisive advantage, enabling rapid breakthroughs in cutting-edge AI applications ranging from military strategy to commercial innovation.“America must remain the global leader in technology—no ifs, no buts,” Trump declared at a recent press conference. “China has been trying to surpass us in AI, but with this new project, we will make sure the future remains ours.”Details regarding funding and governance remain scarce, but early indications suggest the initiative will rely heavily on public-private partnerships, tax incentives for research and development, and collaboration with high-profile venture capital firms. Skeptics, however, warn that the endeavour could fan the flames of an increasingly militarised AI race, raising ethical concerns about surveillance, automation of warfare, and data privacy. Critics also question whether the initiative can deliver on its lofty promises, especially in the face of existing economic and geopolitical pressures.Yet for its supporters, the Stargate Project serves as a rallying cry for renewed American leadership and an antidote to worries over China’s technological ascendancy. Proponents argue that accelerating AI research is paramount if the United States wishes to preserve not just military supremacy, but also the economic and cultural influence that has typified its global role for decades.Whether this bold project will succeed—or if it will devolve into a symbolic gesture—remains to be seen. What is certain, however, is that the Stargate Project has already reignited debate about how best to safeguard America’s strategic future and maintain the balance of power in the fast-evolving arena of artificial intelligence.

Fentanyl trade unravels

Fentanyl, a synthetic opioid up to 50 times more powerful than heroin, has been at the centre of a catastrophic overdose crisis. After years of relentless expansion, the market that once claimed tens of thousands of lives annually is contracting. Preliminary data from the United States Centers for Disease Control and Prevention (CDC) indicate that estimated drug overdose deaths fell to about 80,000 in 2024, a 27 per cent decline from the record of more than 110,000 in 2023, signalling the largest one‑year drop in modern history. This article examines why the fentanyl business is faltering, exploring the interlocking impacts of supply‑chain disruption, international diplomacy, law‑enforcement operations and public‑health initiatives.From Peak to DownturnDuring the early 2020s, illicitly manufactured fentanyl flooded the North American drug market, becoming the leading cause of overdose deaths. The pandemic exacerbated the situation: social isolation and disrupted addiction treatment services contributed to a spike of nearly 110,000 U.S. overdose deaths in 2023. Most of those deaths involved fentanyl, which dealers used to replace or adulterate heroin, counterfeit prescription pills and cocaine. Yet by 2024 the tide had turned. CDC data show that overdose deaths fell by roughly 30,000 in one year, and preliminary numbers for 2025 suggest the decline is continuing. The decrease extends across most U.S. states, with notable reductions in Ohio and West Virginia. Such a sustained downward trend had not been seen in decades and prompted researchers to look beyond domestic policy interventions for an explanation.Supply‑Chain Disruption and China’s CrackdownOne of the most significant drivers of the decline appears to be a disruption in the global supply of fentanyl and its precursors. Researchers analysing death trends in the United States and Canada found evidence of a sudden shortage of fentanyl on illicit markets beginning in mid‑2023. A Science journal study led by scholars at Stanford and the University of Maryland concluded that Chinese enforcement actions against chemical suppliers have curtailed exports of fentanyl precursors. Officials in Beijing shut down hundreds of companies, removed tens of thousands of online advertisements and arrested about 300 people after agreements with Washington to restrict the trade. The research suggests these moves reduced the availability of 4‑fluoroisobutyryl fentanyl and other precursors, causing the purity of seized fentanyl to fall and the price to rise. According to the DEA’s 2025 National Drug Threat Assessment, some Chinese suppliers have become wary of shipping controlled chemicals, aware that their government is enforcing updated counter‑narcotics treaties. Mexican fentanyl cooks report difficulty obtaining key precursors and are increasingly relying on designer chemicals to circumvent regulations.Cartel Disruption and EnforcementWhile precursor shortages have choked production, targeted law‑enforcement operations have also shaken the industry. White papers from the National Security Data and Policy Institute detail how the capture of Ovidio Guzmán López — a senior Sinaloa Cartel figure and son of Joaquín "El Chapo" Guzmán — in 2023 destabilised the cartel’s synthetic‑drug division. Experts point to a correlation between cartel ‘decapitation’ operations and sharp but temporary declines in fentanyl seizures and overdose deaths. The killing of Nemesio Oseguera Cervantes, leader of the Jalisco New Generation Cartel in late 2025, likewise rattled the market, although researchers caution that rival factions can quickly reconstitute production. The National Drug Threat Assessment notes that the Sinaloa and Jalisco cartels continue to dominate fentanyl production, but they face greater risk as Mexican and U.S. authorities cooperate to target laboratories and intercept shipments at the southwest border. Seizures at border crossings dropped from 29,000 kilograms in 2023 to 23,000 kilograms in 2024, reinforcing evidence of a supply contraction.Public‑Health Measures and Changing BehaviourThe contraction of the fentanyl trade has amplified the effect of public‑health interventions. Increased distribution of the overdose‑reversal drug naloxone, expansion of medication‑assisted treatment programmes and billions of dollars in opioid settlement funds have collectively improved survival rates. Harm‑reduction services such as supervised consumption sites and drug‑checking kits have proliferated in major cities, allowing users to detect dangerous adulterants like xylazine and medetomidine. Younger Americans appear less likely to initiate opioid use than previous cohorts, and some long‑term users have died or shifted consumption patterns. These behavioural changes mean that a shrinking pool of susceptible individuals is exposed to an increasingly fragmented drug supply.An Evolving Drug MarketDespite the current downturn, the illicit drug market is far from static. The DEA warns that declining fentanyl purity does not equate to reduced danger. To compensate for shortages, traffickers are mixing fentanyl with veterinary tranquilizers and new synthetic opioids such as nitazenes, which can be even more potent. The National Security Data and Policy Institute notes that precursor chemicals still arrive in Mexico’s Pacific ports such as Manzanillo, and cartels are diversifying sourcing through India and alternative trans‑shipment points. According to the DEA, the presence of xylazine in seized powder has risen steadily since 2020, increasing the risk of fatal respiratory depression and flesh‑rotting wounds. Nitazene analogues and other novel substances are appearing in toxicology reports at an accelerating rate in 2026, underscoring how quickly manufacturers pivot when confronted with enforcement pressure.The sharp decline in fentanyl‑related deaths offers a glimmer of hope after years of escalating tragedy, but it is not a definitive victory. The current contraction appears to be driven primarily by disruptions in precursor supply, strategic cartel‑targeting operations and strengthened public‑health responses. Yet the same agility that allowed traffickers to flood markets with fentanyl enables them to adapt to enforcement, shifting to new chemicals, routes and business models. Sustained reductions in opioid mortality will require international cooperation to control chemical exports, continued pressure on manufacturing networks, wider access to treatment and harm‑reduction services, and public education to deter drug initiation. As policy makers debate how to allocate resources, the lesson of the fentanyl collapse is clear: comprehensive, co‑ordinated action across borders and disciplines can save lives.